Literature DB >> 21533742

Polytherapy for the prophylaxis of chronic migraine: an Italian survey.

D D'Amico1, M Curone, V Tullo, A Proietti Cecchini, E Mea, G Bussone.   

Abstract

Chronic migraine (CM) represents an important medical issue, due to morbidity, high disability, presence of comorbidities, and medication overuse (MO). The prophylaxis of CM has not been extensively explored so far. Patients with CM are often treated with two or more compounds, although there is no clear evidence that polytherapy may be superior to monotherapy. We evaluated the percentage of prescription of polytherapy for the prophylaxis of CM in a clinical sample. We examined the charts of 98 CM patients admitted to our Headache Center for inpatient withdrawal program to stop MO. Results showed that only one drug for prophylaxis was prescribed in 20.4% cases, two or more drugs in 79.6%, with 63.3% of the total sample falling in the group "true polytherapy", i.e. all the drugs prescribed on daily basis were given to treat CM, and not only to treat concomitant conditions. In more than 60% cases a combination of drugs indicated for migraine prophylaxis and drugs only indicated for other conditions (mainly for psychiatric disorders) was prescribed. Our survey indicates that polytherapy may be rather common in CM, and suggests that comorbidities may strongly influence treatment choices.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533742     DOI: 10.1007/s10072-011-0521-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  16 in total

1.  Incidence and predictors for chronicity of headache in patients with episodic migraine.

Authors:  Z Katsarava; S Schneeweiss; T Kurth; U Kroener; G Fritsche; A Eikermann; H-C Diener; V Limmroth
Journal:  Neurology       Date:  2004-03-09       Impact factor: 9.910

Review 2.  Dynamic optimization of chronic migraine treatment: current and future options.

Authors:  Ninan T Mathew
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910

3.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

4.  Testing the combination beta-blocker plus topiramate in refractory migraine.

Authors:  J Pascual; M T Rivas; R Leira
Journal:  Acta Neurol Scand       Date:  2007-02       Impact factor: 3.209

5.  Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials.

Authors:  Domenico D'Amico
Journal:  Neurol Sci       Date:  2010-06       Impact factor: 3.307

6.  Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study.

Authors:  Abouch Valenty Krymchantowski; Marcus Tulius Silva; Jackeline Soraya Barbosa; Luiz Anastácio Alves
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

Review 7.  What predicts the change from episodic to chronic migraine?

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

8.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

9.  Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.

Authors:  Marcelo E Bigal; Daniel Serrano; Michael Reed; Richard B Lipton
Journal:  Neurology       Date:  2008-08-19       Impact factor: 9.910

10.  Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers.

Authors:  D C Buse; A Manack; D Serrano; C Turkel; R B Lipton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-02-17       Impact factor: 10.154

View more
  2 in total

Review 1.  Controversies in migraine: monotherapy.

Authors:  Domenico D'Amico
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

2.  Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder.

Authors:  Marcella Curone; V Tullo; M Savino; A Proietti-Cecchini; G Bussone; D D'Amico
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.